Compare Recursion Pharmaceuticals Inc (RXRX) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs ProShares Ultra Gold ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.24 (market cap $1.86B), while ProShares Ultra Gold ETF trades at $51.7. The key difference: ProShares Ultra Gold ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | UGL | |
|---|---|---|
Market Cap | $1.86B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $6.79 | $85.62 |
52-Week Low | $2.84 | $41.14 |
Enterprise Value | $1.38B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
UGL shares declined 3.43% to $50.61, reflecting bearish technical momentum with the stock trading near key support levels. The technical picture shows oversold conditions with RSI at 25.52 suggesting potential near-term bounce, while moving averages indicate sustained downward pressure. Recent gold market volatility driven by inflation data and Fed policy expectations creates headwinds for gold-related equities.
The outlook remains cautious as UGL faces pressure from rising interest rate expectations and gold price volatility. Investment opportunity exists for contrarian investors given oversold technical conditions, but risks include persistent Fed hawkishness and gold price weakness. Key catalysts include upcoming inflation data and Fed policy decisions that will drive gold market direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
